Search results for "Expert Testimony"

showing 10 items of 24 documents

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension…

2016

Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC),1 the ESH and the European Union Geriatric Medicine Society have created a common working group to examine the management of hypertensive subjects aged >80 years. The general term hypertension in the elderly is not sufficiently accurate because it mixes younger old patients (60–70 years) with the oldest old. Our group believes that the management of hypertension in individuals aged ≥80 years should be specifically addressed. Although arbitrary, this cutoff value identifies a population that is expanding …

MaleGerontologyBLOOD-PRESSUREL-ARGININE TRANSPORTFAT-FED RABBITS030204 cardiovascular system & hematologySeverity of Illness IndexSYMPATHETIC-NERVE ACTIVITY0302 clinical medicine80 and overPerindopril030212 general & internal medicineDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUSMETABOLIC SYNDROMEmedia_commonAged 80 and overGeriatricseducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyIndapamideDisease ManagementPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthAntihypertensive AgentTreatment OutcomeHypertensionPractice Guidelines as TopicFemaleSurvival AnalysiHumanmedicine.drugANGIOTENSIN-CONVERTING ENZYMEmedicine.medical_specialtyPrognosiFrail ElderlyeducationPopulationRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicalInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean UnionNITRIC-OXIDE SYNTHASEEuropean unioneducationREDUCES OXIDATIVE STRESSExpert TestimonyGeriatric AssessmentAntihypertensive AgentsAgedAged; Aged 80 and over; Antihypertensive Agents; Blood Pressure Determination; Disease Management; European Union; Expert Testimony; Female; Frail Elderly; Geriatric Assessment; Geriatrics; Humans; Hypertension; Male; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Survival Analysis; Treatment Outcome; Practice Guidelines as Topic; Internal Medicinebusiness.industryBlood Pressure DeterminationSurvival AnalysisBlood pressureOBESITY-INDUCED HYPERTENSIONGeriatrics3121 General medicine internal medicine and other clinical medicineENDOTHELIAL DYSFUNCTIONLife expectancySocietiesbusinessGeriatric[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHypertension
researchProduct

Expert witness in paternity testing in Germany.

2003

In Germany, paternity testing can be ordered by a judge as well as by private persons. In the case of private counselling, the expert has the duty to inform the parties on all medical, legal and ethical aspects. Informed consent must be given by each individual included in an exploration of family relationships. Due to the rapid progress of DNA typing in even minute amounts after polymerase chain reaction amplification, genotypes of short tandem repeat systems can be elicited by extraction from single cells. Therefore, the number of unlawful investigations of paternal relationships is steadily increasing. Here the requirements for paternity testing laboratories and sanctions for unlawful ex…

Malebusiness.industrymedia_common.quotation_subjectPaternityDNA FingerprintingFederal lawPathology and Forensic MedicineIssues ethics and legal aspectsDNA profilingExpert witnessInformed consentLawGermanyForensic engineeringMedicineSanctionsMicrosatelliteHumansbusinessDutyExpert Testimonymedia_commonLegal medicine (Tokyo, Japan)
researchProduct

Classification of neuropathic pain in cancer patients: A Delphi expert survey report and EAPC/IASP proposal of an algorithm for diagnostic criteria

2014

Neuropathic pain (NP) in cancer patients lacks standards for diagnosis. This study is aimed at reaching consensus on the application of the International Association for the Study of Pain (IASP) special interest group for neuropathic pain (NeuPSIG) criteria to the diagnosis of NP in cancer patients and on the relevance of patient-reported outcome (PRO) descriptors for the screening of NP in this population. An international group of 42 experts was invited to participate in a consensus process through a modified 2-round Internet-based Delphi survey. Relevant topics investigated were: peculiarities of NP in patients with cancer, IASP NeuPSIG diagnostic criteria adaptation and assessment, and …

Malemedicine.medical_specialtyConsensusPalliative careDelphi TechniquePopulationDelphi methodPhysical examinationInterquartile rangePain assessmentNeoplasmsSurveys and QuestionnairesHumansMedicineeducationExpert TestimonyPain MeasurementInterneteducation.field_of_studymedicine.diagnostic_testbusiness.industryPalliative CareCancermedicine.diseaseHealth SurveysAnesthesiology and Pain MedicineNeurologyPhysical therapyNeuralgiaFemaleNeurology (clinical)businessCancer painAlgorithmAlgorithmsPain
researchProduct

Identification of an Unknown Corpse by Means of Computed Tomography (CT) of the Lumbar Spine

1995

For the first time, a case is described in which an unknown corpse is identified by the comparison of antemortem and postmortem computed tomographic (CT) images. A posterolateral disc herniation at L5-S1 on the right side, Schmorl's nodes and a lucency in the ilium were found in identical locations in each case. Additionally there were characteristic morphological similarities in the vertebral bodies, spinous processes, transverse processes and neural arches. In CT identification, as in conventional radiographic identification, one must try to reproduce comparable scanning conditions and images because apparent differences in the roentgenological morphology can occur as a result of differen…

Malemedicine.medical_specialtyDisc herniationRadiographyComputed tomographyPathology and Forensic MedicineComputed tomographicIliumX ray computedGeneticsmedicineHumansExpert TestimonyLumbar Vertebraemedicine.diagnostic_testbusiness.industryAnatomyMiddle AgedPostmortem ChangesLumbar spineTomographyRadiologyHomicideTomography X-Ray ComputedbusinessIntervertebral Disc DisplacementJournal of Forensic Sciences
researchProduct

The decision support system for telemedicine based on multiple expertise

1998

This paper discusses the application of artificial intelligence in telemedicine and some of our research results in this area. The main goal of our research is to develop methods and systems to collect, analyse, distribute and use medical diagnostics knowledge from multiple knowledge sources and areas of expertise. Use of modern communication tools enable a physician to collect and analyse information obtained from experts worldwide with the help of a decision support medical system. In this paper we discuss a multilevel representation and processing of medical data using a system which evaluates and exploits knowledge about the behaviour of statistical diagnostics methods. The presented te…

Medical algorithmDecision support systemTelemedicineMedical diagnosticExploitComputer sciencebusiness.industryRemote ConsultationHealth Informaticscomputer.software_genreData scienceExpert systemKnowledge baseArtificial IntelligenceHumansData miningRepresentation (mathematics)businessExpert TestimonycomputerAlgorithmsDecision Making Computer-AssistedInternational Journal of Medical Informatics
researchProduct

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

2021

Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. W…

Non-Hormonal Preparationsmedicine.medical_specialtyChronic conditionmedicine.drug_classmedicine.medical_treatmentUrinary systemVaginal DiseasesUrinary incontinenceVulvovaginal atrophyGeneral Biochemistry Genetics and Molecular BiologyVulvovaginal Atrophy03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineHumansEndocrine system030212 general & internal medicineExpert Testimony030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyEstrogensPostmenopauseTopical EstrogensAdministration IntravaginalEstrogenPractice Guidelines as TopicQuality of LifeFemaleVulvar DiseasesAtrophymedicine.symptombusinessAdjuvantMaturitas
researchProduct

Ten important articles on noninvasive ventilation in critically ill patients and insights for the future: A report of expert opinions

2017

Background Noninvasive ventilation is used worldwide in many settings. Its effectiveness has been proven for common clinical conditions in critical care such as cardiogenic pulmonary edema and chronic obstructive pulmonary disease exacerbations. Since the first pioneering studies of noninvasive ventilation in critical care in the late 1980s, thousands of studies and articles have been published on this topic. Interestingly, some aspects remain controversial (e.g. its use in de-novo hypoxemic respiratory failure, role of sedation, self-induced lung injury). Moreover, the role of NIV has recently been questioned and reconsidered in light of the recent reports of new techniques such as high-fl…

Research Reportmedicine.medical_specialtyExacerbationCritical CareCPAP; Non invasive ventilation; Respiratory failure; Critical Care; Critical Illness; Expert Testimony; Forecasting; Humans; Noninvasive Ventilation; Randomized Controlled Trials as Topic; Research Report; Surveys and Questionnaires; Anesthesiology and Pain MedicineCritical IllnessCPAP; Non invasive ventilation; Respiratory failure; Anesthesiology and Pain MedicinePatient characteristicsLung injuryRespiratory failure[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractlaw.inventionlcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineRandomized controlled triallawCPAPAnesthesiologySurveys and QuestionnairesSettore MED/41 - ANESTESIOLOGIAmedicineHumans030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineExpert TestimonyRandomized Controlled Trials as TopicNoninvasive VentilationCritically illbusiness.industryNon invasive ventilation3. Good healthAnesthesiology and Pain Medicine030228 respiratory systemRespiratory failurelcsh:AnesthesiologyCritical Illne[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractNoninvasive ventilationCPAP; Non invasive ventilation; Respiratory failurebusinessHumanResearch ArticleForecasting
researchProduct

Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?

2017

Introduction: Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies. Expert commentary: The difficult pathogenic scenario of MAS, in which genetic defects, predisposing diseases, and triggers are mixed together with the high mortality rat…

adult onset Still’s disease0301 basic medicineAdultAdult-onset Still's diseasemedicine.medical_treatmentImmunologyInflammationmacrophagemacromolecular substancesDisease03 medical and health sciences0302 clinical medicineRheumatic DiseasescytokinemedicineImmunology and AllergyMacrophageAnimalsHumanssystemic juvenile idiopathic arthritiMolecular Targeted TherapyChildExpert Testimony030203 arthritis & rheumatologyInflammationbusiness.industrymusculoskeletal neural and ocular physiologyMacrophage Activation Syndromehyperferritinemic syndromeMacrophage Activationmedicine.diseaseSettore MED/16 - Reumatologia030104 developmental biologyCytokinenervous systemMacrophage activation syndromeImmunologymedicine.symptombusinessExpert review of clinical immunology
researchProduct

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diab…

2017

Aims These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. Methods The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method …

lcsh:Diseases of the circulatory (Cardiovascular) systemKeywords: Anti-glycaemic drugs ; Cardiovascular disease ; Renal disease ; Type 2 diabetesmedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and DiabetologyDelphi method610 Medicine & health030209 endocrinology & metabolismReviewType 2 diabetesDisease030204 cardiovascular system & hematologyAnti-glycaemic drugs2705 Cardiology and Cardiovascular MedicineTranslational Research BiomedicalRenal disease03 medical and health sciences0302 clinical medicineMultidisciplinary approachDiabetes mellitusDiabetes MellitusmedicineHumansHypoglycemic AgentsEurope EasternIntensive care medicineExpert TestimonyClinical Trials as Topicbusiness.industryType 2 diabetesCardiovascular diseasemedicine.diseaseExpert groupEuropeEastern european2712 Endocrinology Diabetes and MetabolismTreatment Outcome2724 Internal MedicineCardiovascular Diseaseslcsh:RC666-701Practice Guidelines as TopicCardiology and Cardiovascular MedicinebusinessKidney diseaseCardiovascular Diabetology
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct